Keri Van Becelaere

2.4k citations

10 papers · 2.0k indexed · 1 hit paper · h-index 7

Co-authors: Judith S. Sebolt–Leopold Román Herrera David T. Dudley Sally Przybranowski Haile Tecle Stephen D. Barrett Wilbur R. Leopold Alexander J. Bridges
Topics: Melanoma and MAPK Pathways (7 papers)PI3K/AKT/mTOR signaling in cancer (5 papers)Cannabis and Cannabinoid Research (2 papers)
Cited by: Toxicology Pharmacology Oncology
Journals: Journal of Biological Chemistry Nature Medicine Journal of Clinical Oncology
Partner nations: United States United Kingdom

In The Last Decade

Keri Van Becelaere

10 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1999 804 citations Judith S. Sebolt–Leopold, David T. Dudley et al. Nature Medicine profile →

Peers

Countries citing papers authored by Keri Van Becelaere

Since Specialization

Citations

This map shows the geographic impact of Keri Van Becelaere's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keri Van Becelaere with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keri Van Becelaere more than expected).

Fields of papers citing papers by Keri Van Becelaere

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keri Van Becelaere. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keri Van Becelaere. The network helps show where Keri Van Becelaere may publish in the future.

Co-authorship network of co-authors of Keri Van Becelaere

This figure shows the co-authorship network connecting the top 25 collaborators of Keri Van Becelaere. A scholar is included among the top collaborators of Keri Van Becelaere based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keri Van Becelaere. Keri Van Becelaere is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Kay Ahn,Sarah E. Smith,Marya Liimatta,David Beidler,Nalini Sadagopan,David T. Dudley,Tim Young,Paul Wren,Yanhua Zhang,Steven Swaney,Keri Van Becelaere,Jacqueline L. Blankman,Daniel K. Nomura,Shobha Bhattachar,Cory M. Stiff,Tyzoon Nomanbhoy,Eranthie Weerapana,Douglas S. Johnson,Benjamin F. Cravatt	191
2	Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain 2009 ·Chemistry & Biology ·Kay Ahn,Douglas S. Johnson,Mauro Mileni,David Beidler,Jonathan Z. Long,Michele K. McKinney,Eranthie Weerapana,Nalini Sadagopan,Marya Liimatta,Sarah E. Smith,Scott E. Lazerwith,Cory M. Stiff,Satwik Kamtekar,Keshab Bhattacharya,Zhang Yan-hua,(unknown),Keri Van Becelaere,Raymond C. Stevens,Benjamin F. Cravatt	373
3	The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 2008 ·Bioorganic & Medicinal Chemistry Letters ·Stephen D. Barrett,Alexander J. Bridges,David T. Dudley,Alan R. Saltiel,James H. Fergus,Cathlin Flamme,Amy M. Delaney,Michael D. Kaufman,S Lepage,Wilbur R. Leopold,Sally Przybranowski,Judith S. Sebolt–Leopold,Keri Van Becelaere,Annette M. Doherty,Robert M. Kennedy,(unknown),(unknown),(unknown),Joseph S. Warmus,Haile Tecle	222
4	Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies 2005 ·Journal of Clinical Oncology ·Patricia LoRusso,Alex A. Adjei,Mary Varterasian,Shirish M. Gadgeel,Joel M. Reid,David Mitchell,Lorelei J. Hanson,Pamela DeLuca,Laura M. Bruzek,Jill Piens,(unknown),Keri Van Becelaere,Román Herrera,Judith S. Sebolt–Leopold,Mark B. Meyer	316
5	A Role for K-ras in Conferring Resistance to the MEK Inhibitor, CI-1040 2005 ·Neoplasia ·(unknown),Keri Van Becelaere,Ping Jiang,Sally Przybranowski,Charles A. Omer,Judith S. Sebolt–Leopold	42
6	PK/PD modeling of biomarker (p-ERK) response and tumor growth to PD 0325901 in a human tumor xenograft mouse model 2004 ·Cancer Research ·Jeffrey R. Koup,Jing Liu,Cho‐Ming Loi,(unknown),Keri Van Becelaere,Sally Przybranowski,(unknown),Judith S. Sebolt–Leopold,Ronald L. Merriman	2
7	Synthesis and SAR development of PD 0325901, a potent and highly bioavailable MEK inhibitor. 2004 ·Cancer Research ·Michael D. Kaufman,Stephen D. Barrett,Cathlin Flamme,Joseph S. Warmus,(unknown),(unknown),(unknown),Haile Tecle,Judith S. Sebolt–Leopold,(unknown),Richard Gowan,Keri Van Becelaere,Ronald L. Merriman,Sally Przybranowski,Jeffrey F. Ohren,Christopher E. Whitehead,Wilbur R. Leopold,Ellen M. Dobrusin,Alexander J. Bridges	1
8	Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro 2003 ·Journal of Biological Chemistry ·Xue Meng,Joya Chandra,David A. Loegering,Keri Van Becelaere,Timothy Kottke,Steven D. Gore,Judith E. Karp,(unknown),Scott H. Kaufmann	43
9	Biomarker Assays for Phosphorylated MAP Kinase: Their Utility for Measurement of MEK Inhibition 2003 ·Humana Press eBooks ·Judith S. Sebolt–Leopold,Keri Van Becelaere,Kenneth E. Hook,Román Herrera	5
10	Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivobreakdown → 1999 ·Nature Medicine ·Judith S. Sebolt–Leopold,David T. Dudley,Román Herrera,Keri Van Becelaere,(unknown),Richard Gowan,Haile Tecle,Stephen D. Barrett,Alexander J. Bridges,Sally Przybranowski,Wilbur R. Leopold,Alan R. Saltiel	804

About Keri Van Becelaere

Keri Van Becelaere is a scholar working on Toxicology, Molecular Biology and Pharmacology, having authored 10 papers that have together received 2.0k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (7 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cannabis and Cannabinoid Research (2 papers). The work is most often cited by research in Toxicology (114 citations), Pharmacology (494 citations) and Oncology (545 citations). Keri Van Becelaere has collaborated with scholars based in United States and United Kingdom. Frequent co-authors include Judith S. Sebolt–Leopold, Román Herrera, David T. Dudley, Sally Przybranowski, Haile Tecle, Stephen D. Barrett, Wilbur R. Leopold, Alexander J. Bridges, Alan R. Saltiel and Richard Gowan. Their work appears in journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact